Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. METHODOLOGY: Data from two ongoing projects were used:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacogenomics
Main Authors: Bergmeijer, Thomas O, Vos, Gerrit JA, Claassens, Daniël MF, Janssen, Paul WA, Harms, Remko, van der Heide, Richard, Asselbergs, Folkert W, ten Berg, Jurriën M, Deneer, Vera HM
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021912/
https://ncbi.nlm.nih.gov/pubmed/29701129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2018-0013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados